Equities research analysts expect Onconova Therapeutics Inc (NASDAQ:ONTX) to announce earnings of ($0.72) per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Onconova Therapeutics’ earnings. Onconova Therapeutics posted earnings per share of ($0.54) in the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The business is expected to announce its next quarterly earnings report on Monday, March 26th.
On average, analysts expect that Onconova Therapeutics will report full-year earnings of ($2.82) per share for the current year. For the next financial year, analysts forecast that the business will report earnings of ($2.06) per share. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Onconova Therapeutics.
Onconova Therapeutics (NASDAQ:ONTX) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.02. The company had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.29 million. Onconova Therapeutics had a negative net margin of 2,855.94% and a negative return on equity of 558.97%.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Onconova Therapeutics by 58.4% in the second quarter. Vanguard Group Inc. now owns 87,940 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 32,418 shares during the period. 683 Capital Management LLC grew its holdings in Onconova Therapeutics by 21.0% in the third quarter. 683 Capital Management LLC now owns 375,000 shares of the biopharmaceutical company’s stock worth $641,000 after purchasing an additional 65,140 shares during the period. Sabby Management LLC grew its holdings in Onconova Therapeutics by 104.0% in the second quarter. Sabby Management LLC now owns 784,000 shares of the biopharmaceutical company’s stock worth $1,693,000 after purchasing an additional 399,640 shares during the period. Finally, Tyndall Capital Partners L P grew its holdings in shares of Onconova Therapeutics by 91.4% during the second quarter. Tyndall Capital Partners L P now owns 997,022 shares of the biopharmaceutical company’s stock valued at $2,154,000 after buying an additional 476,190 shares during the last quarter. Institutional investors and hedge funds own 25.44% of the company’s stock.
Shares of Onconova Therapeutics (NASDAQ ONTX) traded down $0.01 on Tuesday, reaching $1.68. 159,300 shares of the company’s stock were exchanged, compared to its average volume of 180,800. The stock has a market capitalization of $18.10, a PE ratio of -0.55 and a beta of 0.10. Onconova Therapeutics has a twelve month low of $1.21 and a twelve month high of $3.88.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/zacks-analysts-anticipate-onconova-therapeutics-inc-ontx-to-post-0-72-eps/1820663.html.
About Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.